Efficacy and safety of brentuximab vedotin plus bendamustine in advanced‐stage primary cutaneous T‐cell lymphomas-Reference-Cited by-同舟云学术

Efficacy and safety of brentuximab vedotin plus bendamustine in advanced‐stage primary cutaneous T‐cell lymphomas

Published:2019-08-22 Issue:6 Volume:181 Page:1315-1317
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Dumont M.¹,Ram‐Wolff C.¹,Roelens M.²,Brice P.³,Peffault de Latour R.⁴,Battistella M.⁵,Madelaine I.⁶,Delyon J.¹,Herms F.¹,Bouaziz J.‐D.¹,Moins‐Teisserenc H.²,Lebbé C.¹,Bagot M.¹,Masson A.¹^ORCID

Affiliation:

1. Departments of Dermatology Saint‐Louis Hospital, AP‐HP, Paris 7 University 1 avenue Claude Vellefaux 75010 Paris France

2. Immunology (Inserm U1160) Saint‐Louis Hospital, AP‐HP, Paris 7 University 1 avenue Claude Vellefaux 75010 Paris France

3. Hemato‐oncology Saint‐Louis Hospital, AP‐HP, Paris 7 University 1 avenue Claude Vellefaux 75010 Paris France

4. Departments of Hematology‐Bone Marrow Transplantation Saint‐Louis Hospital, AP‐HP, Paris 7 University 1 avenue Claude Vellefaux 75010 Paris France

5. Departments of Pathology (Inserm U976) Saint‐Louis Hospital, AP‐HP, Paris 7 University 1 avenue Claude Vellefaux 75010 Paris France

6. Pharmacy Saint‐Louis Hospital, AP‐HP, Paris 7 University 1 avenue Claude Vellefaux 75010 Paris France

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.18215

Reference8 articles.

1. Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas

2. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

3. Results From a Prospective, Open-Label, Phase II Trial of Bendamustine in Refractory or Relapsed T-Cell Lymphomas: The BENTLY Trial

4. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial

5. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathophysiology of cutaneous T-cell lymphomas: Perspective from a French referral centre;Immunology Letters;2024-08

2. Aggressive Form of Mycosis Fungoides With Bilateral Testicular Involvement and Salivary Gland Mass, Exhibiting Phenotypic Switch;The American Journal of Dermatopathology;2024-07-12

3. Syndrome de Sézary;Hématologie;2024-01-01

4. Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA;Blood Advances;2022-12-07

5. Bendamustine monochemotherapy in aggressive or advanced‐stage primary cutaneous T‐cell lymphomas;Journal of the European Academy of Dermatology and Venereology;2022-11-10